|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
MUSCLE CELL BIOLOGY AND CELL MOTILITY
q-dependent PLC-
1 activity by PKG and PKA is mediated by phosphorylation of RGS4 and GRK2
Departments of Physiology and Medicine, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, Virginia
Submitted 3 March 2006 ; accepted in final form 24 July 2006
| ABSTRACT |
|---|
|
|
|---|
1 to stimulate phosphoinositide (PI) hydrolysis and inositol 1,4,5-trisphosphate (IP3) generation and induce IP3-dependent Ca2+ release. Inhibition of Ca2+ mobilization by cAMP- (PKA) and cGMP-dependent (PKG) protein kinases reflects inhibition of PI hydrolysis by both kinases and PKG-specific inhibitory phosphorylation of IP3 receptor type I. The mechanism of inhibition of PLC-
1-dependent PI hydrolysis has not been established. Neither Gq nor PLC-
1 was directly phosphorylated by PKA or PKG in gastric smooth muscle cells. However, both kinases 1) phosphorylated regulator of G protein signaling 4 (RGS4) and induced its translocation from cytosol to plasma membrane, 2) enhanced ACh-stimulated association of RGS4 and G
q·GTP and intrinsic G
q·GTPase activity, and 3) inhibited ACh-stimulated PI hydrolysis. RGS4 phosphorylation and inhibition of PI hydrolysis were blocked by selective PKA and PKG inhibitors. Expression of RGS4(S52A), which lacks a PKA/PKG phosphorylation site, blocked the increase in GTPase activity and the decrease in PI hydrolysis induced by PKA and PKG. Blockade of PKA-dependent effects was only partial. Selective phosphorylation of G protein-coupled receptor kinase 2 (GRK2), which contains a RGS domain, by PKA augmented ACh-stimulated GRK2:G
q·GTP association; both effects were blocked in cells expressing GRK2(S685A), which lacks a PKA phosphorylation site. Inhibition of PI hydrolysis induced by PKA was partly blocked in cells expressing GRK2(S685A) and completely blocked in cells coexpressing GRK2(S685A) and RGS4(S52A) or G
q(G188S), a G
q mutant that binds GRK2 but not RGS4. The results demonstrate that inhibition of PLC-
1-dependent PI hydrolysis by PKA is mediated via stimulatory phosphorylation of RGS4 and GRK2, leading to rapid inactivation of G
q·GTP. PKG acts only via phosphorylation of RGS4. regulators of G protein signaling; G protein-coupled receptor kinase 2; phospholipase C; cAMP-dependent protein kinase; cGMP-dependent protein kinase
1 via G
q or PLC-
3 via G
i, leading to generation of inositol 1,4,5-trisphosphate (IP3) and IP3-dependent Ca2+ release (18). The resultant increase in cytosolic Ca2+ [Ca2+]i activates Ca2+/calmodulin-dependent myosin light chain (MLC) kinase, leading to phosphorylation of MLC20, a prerequisite for smooth muscle contraction (11, 33). This Ca2+-dependent phase is followed by sustained contraction during which MLC20 phosphorylation is maintained by a Ca2+-independent MLC kinase and MLC phosphatase is inhibited via a RhoA-dependent cascade (18, 33). Relaxation of contracted smooth muscle is mediated by cAMP- or cGMP-dependent protein kinase (PKA or PKG), which acts on several targets in the signaling cascades to induce dephosphorylation of MLC20 (1, 15, 32). Relaxation of initial contraction correlates with the decrease in [Ca2+]i, which could occur as the result of a decrease in IP3 generation and/or inhibition of IP3-induced Ca2+ release (16, 24). Only PKG is capable of phosphorylating IP3 receptor type I (IP3R-I) and inhibiting IP3-induced Ca2+ release, whereas both PKA and PKG are capable of inhibiting IP3 generation (12, 26, 27).
Several studies have examined whether inhibition of IP3 generation reflects inhibitory phosphorylation of PLC-
(2, 17, 37, 38). In various cell lines transfected with G protein subunits and PLC-
isozymes, phosphorylation of Ser26 and/or Ser1105 in PLC-
3 by PKA or PKG inhibited G
q- or G
i-stimulated PLC-
3 activity (37, 38). However, in cell lines or native cells, PLC-
1 is not phosphorylated in vivo or in vitro by PKA or PKG (37). In smooth muscle cells, PLC-
3 is preferentially activated by G
i, whereas PLC-
1 is selectively activated by G
q (20, 22, 25, 28). The mechanism by which PLC-
1 activity is inhibited by PKA or PKG could reflect a proximal step, such as inhibitory phosphorylation of G
q or stimulatory phosphorylation of a RGS protein.
The strength and duration of G
·GTP signaling are regulated by a family of GTPase-activating proteins known as regulators of G protein signaling (RGS) (8). The proteins contain a RGS domain, capable of binding to activated G
subunits and accelerating their intrinsic GTPase activity. Smooth muscle cells of the gut express several RGS proteins, including RGS3, RGS4, RGS6, RGS8, RGS12, and RGS16 (Huang J and Murthy KS, unpublished studies). Activation of G
q in these cells is regulated by RGS4 (10).
In the present study, we have shown that both PKA and PKG phosphorylated RGS4, enhancing its ability to bind G
q, and accelerated the intrinsic GTPase activity of G
q·GTP. Furthermore, PKA, but not PKG, phosphorylated G protein-coupled receptor kinase 2 (GRK2), which contains a RGS-like domain, enhancing its ability to bind G
q and accelerate the intrinsic GTPase activity of G
q·GTP. The rapid inactivation of G
q via phosphorylation of GRK2 and/or RGS4 resulted in inhibition of PLC-
1 activity. The results provide firm evidence that PKA inhibits PLC-
1 activity by phosphorylating both RGS4 and GRK2, thereby enhancing their ability to accelerate deactivation of G
q·GTP. In contrast, PKG inhibits PLC-
1 activity by phosphorylating RGS4 only.
| MATERIALS AND METHODS |
|---|
|
|
|---|
RGS4, GRK2, and G
q mutant constructs.
The following mutants were constructed: 1) RGS4(S52A), which lacks a PKA/PKG phosphorylation site, 2) G
q(G188S), which binds GRK2 but not RGS protein (57), and 3) GRK2(S685A), which lacks a PKA phosphorylation site. These constructs were subcloned separately into the multiple cloning site (EcoRI) of the eukaryotic expression vector pEXV. Recombinant plasmid DNAs (2 µg each) were transiently transfected into cultured smooth muscle cells in first passage with the use of Lipofectamine Plus reagent for 48 h. The cells were cotransfected with 1 µg of pGreen Lantern-1 to monitor expression. Control cells were cotransfected with 2 µg of vector (pEXV) and 1 µg of pGreen Lantern-1 DNA. Transfection efficiency (
75%) was monitored by the expression of green fluorescent protein using FITC filters (28, 29).
Assay of phosphoinositide hydrolysis. Phosphoinositide (PI) hydrolysis was measured as total inositol phosphate formation with the use of anion exchange chromatography as described previously (20, 22, 28). Freshly dispersed and cultured smooth muscle cells were labeled with myo-2-[3H]inositol (0.5 µCi/ml) in inositol-free medium. Muscle cells (2 x 106 cells) were treated with isoproterenol or sodium nitroprusside (SNP) for 10 min and then with acetylcholine (ACh) for 60 s in 1 ml of 25 HEPES medium containing 115 mM NaCl, 5.8 mM KCl, 2.1 mM KH2PO4, 2 mM CaCl2, 0.6 mM MgCl2, and 14 mM glucose. The reaction was terminated by the addition of 940 µl of chloroform-methanol-HCl (50:100:1). After extraction with 340 µl of chloroform and 340 µl of H2O, the aqueous phase was applied to DOWEX AG-1 columns. [3H]inositol phosphates were then eluted, and the radioactivity was determined by liquid scintillation.
Protein phosphorylation (RGS4, GRK2, PLC-
1, PLC-
3, and G
q).
Phosphorylation of specific proteins was determined from the amount of 32P incorporated into each protein after immunoprecipitation with specific antibody to RGS4, GRK2, PLC-
1, PLC-
3, or G
q. Briefly, cultured muscle cells were incubated with [32P]orthophosphate for 24 h, whereas freshly dispersed cells were incubated with [32P]orthophosphate for 4 h (21). Samples (1 ml) were then incubated with isoproterenol or SNP for 10 min in the presence or absence of inhibitors for PKA (myristoylated PKI) and PKG [Rp-8-(4-chlorophenylthio)guanosine 3',5'-cyclic monophosphate (Rp-cGMPS)] (21). Cell lysates were separated by centrifugation at 13,000 g for 10 min at 4°C, precleared with 40 µl of protein A-Sepharose, and incubated with RGS4, GRK2, G
q, PLC-
1, or PLC-
3 antibody for 2 h at 4°C and with 40 µl of protein A-Sepharose for another 1 h. The immunoprecipitates were extracted with Laemmli sample buffer, boiled for 5 min, and separated by electrophoresis on SDS-PAGE. After transfer to polyvinylidene difluoride (PVDF) membranes, [32P]RGS4, [32P]GRK2, [32P]G
q, [32P]PLC-
1, or [32P]PLC-
3 was visualized by autoradiography, and the amount of radioactivity in the band was measured using liquid scintillation. The results were expressed as counts per minute (cpm).
Immunoblot analysis of G
q-bound RGS4 and GRK2 proteins.
Smooth muscle cells (3 x 106 cells/ml) treated with ACh in the presence of isoproterenol or SNP were lysed by incubation for 30 min at 4°C in 10 mM Tris (pH 7.5), 50 mM NaCl, 1% Triton X-100, and 60 mM octyl glucoside, and the lysates were centrifuged at 15,000 g for 30 min. The supernatant was precleared by incubation with 40 µl of protein A-Sepharose for 4 h and then incubated overnight with the antibody to RGS4 or GRK2. Protein A-Sepharose was then added and incubated for another 2 h, and the mixture was centrifuged at 13,000 g for 5 min. The immunoprecipitates were washed four times in lysis buffer and boiled in Laemmli buffer. Samples were separated by SDS-PAGE, transferred to PVDF membranes, and probed with antibody to G
q subunit. After incubation with secondary antibody, the proteins were visualized. The intensity of the protein band on ECL film was determined using densitometry.
For translocation of RGS4 proteins, cells were treated with SNP or isoproterenol for different periods and the amount of RGS4 in cytosol and membrane fractions was quantified by Western blot analysis. Cell homogenates were prepared from freshly dispersed gastric smooth muscle cells in Tris·HCl (pH 7.5) medium containing 5 mM MgCl2, 2 mM EDTA, 250 mM sucrose, 1 mM DTT, 1 mM PMSF, 20 µg/ml of leupeptin, and 20 µg/ml aprotinin. The suspension was centrifuged at 100,000 g for 30 min at 4°C, and the supernatant was collected as the cytosolic fraction. Pellets were suspended in Tris·HCl buffer medium containing 1% Triton X-100 and 1% sodium cholate. The extract was centrifuged at 1,000 g for 15 min, and the supernatant was collected as membrane fraction. Cytosolic and membrane proteins were resolved by SDS-PAGE, electrophoretically transferred onto PVDF membrane, and probed with RGS4 antibody. The bands were identified using enhanced chemiluminescence.
Assay for GTPase activity. GTPase activity was measured in smooth muscle membranes as described previously (30). Smooth muscle cells were incubated with ACh in the presence or absence of isoproterenol or SNP for various time periods. An equal amount of the membrane protein was incubated with 0.4 µCi of [32P]GTP for 30 min at 31°C. The reaction was terminated by the addition of 750 µl of 5% activated charcoal containing 20 mM phosphoric acid, and after centrifugation at 6,000 g for 15 min, the amount of radioactivity in the supernatant (500 µl) was counted by liquid scintillation. Nonspecific release of 32P in the absence of membrane protein was subtracted from the values. The results were expressed as counts per minute.
[3H]scopolamine binding to smooth muscle cells. Binding of [3H]scopolamine to dispersed muscle cells was done as described previously (23). Muscle cells were suspended in HEPES medium containing 1% bovine serum albumin. Triplicate 0.5-ml (106 cell/ml) aliquots were incubated for 15 min with 1 nM [3H]scopolamine alone or in the presence of 10 µM ACh. Bound and free radioligands were separated by rapid filtration under reduced pressure through 5-µm polycarbonate Nucleophore filters. Nonspecific binding was calculated as the amount of radioactivity in the presence of 10 µM ACh. [3H]scopolamine binding was measured in the control cells and in cells pretreated for 10 min with isoproterenol or SNP.
Measurement of relaxation in dispersed smooth muscle cells. Inhibition of ACh-induced contraction (i.e., relaxation) by SNP or isoproterenol was expressed as the decrease in maximal cell contraction induced by 0.1 µM ACh (2426). The mean cell length of 50 muscle cells treated with ACh alone or in the presence of SNP (1 µM) or isoproterenol (1 µM) was measured using scanning micrometry and was compared with the length of untreated muscle cells (mean control cell length 102 ± 3 µM).
Materials.
Myo-[3H]inositol and [32P]orthophosphate were obtained from NEN Life Sciences Products (Boston, MA). Polyclonal antibodies to G
q, PLC-
1, PLC-
3, RGS4, and GRK2 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Western blotting and chromatography material were obtained from Bio-Rad Laboratories (Hercules, CA). Collagenase and soybean trypsin inhibitor were obtained from Worthington Biochemical (Freehold, NJ). All other reagents were obtained from Sigma.
| RESULTS |
|---|
|
|
|---|
As shown previously, ACh acts via Gq-coupled m3 receptors to activate PLC-
1 and via Gi3-coupled m2 receptors to activate PLC-
3 (28). In the presence of the m2 receptor antagonist methoctramine, ACh caused a concentration-dependent increase in PI hydrolysis in freshly dispersed smooth muscle cells (Fig. 1). Pretreatment of the cells with isoproterenol or SNP inhibited ACh-stimulated PI hydrolysis: the inhibition by isoproterenol was selectively blocked by myristoylated PKI, whereas the inhibition by SNP was selectively blocked by Rp-cGMPS (Fig. 1). Inhibition of maximally stimulated PI hydrolysis by isoproterenol (EC50 25 nM) and SNP (EC50 60 nM) was concentration dependent. These results suggested that selective activation of PKA by isoproterenol and PKG by SNP inhibited PI hydrolysis. Inhibition of maximally stimulated PI hydrolysis by isoproterenol and SNP was time dependent: inhibition was significant within 2 min (61 ± 5% with SNP and 68 ± 5% with isoproterenol) and reached a peak within 5 min (78 ± 6% with SNP and 82 ± 4% with isoproterenol) that was sustained for 10 min.
|
q and PLC-
phosphorylation. Treatment of dispersed smooth muscle cells with isoproterenol (1 µM) or SNP (1 µM) had no effect on [3H]scopolamine binding (control specific binding: 1,835 ± 265 cpm; SNP: 1,769 ± 302 cpm; isoproterenol: 1,802 ± 274 cpm) and did not induce phosphorylation of G
q or PLC-
1. Both agents, however, induced phosphorylation of PLC-
3 (data not shown) as reported previously (37, 38).
Phosphorylation of RGS4 by PKA and PKG and stimulation of RGS4:G
q·GTP association.
Both isoproterenol and SNP phosphorylated RGS4 in freshly dispersed smooth muscle cells. Phosphorylation by isoproterenol was inhibited by myristoylated PKI but was not affected by Rp-cGMPS, whereas phosphorylation by SNP was inhibited by Rp-cGMPS but was not affected by myristoylated PKI (Fig. 2).
|
q. In the presence of ACh, however, translocation of RGS4 to the membrane upon phosphorylation by PKA or PKG resulted in greater association of RGS4 with membrane-bound, activated G
q·GTP (Fig. 4). The pattern demonstrated that RGS4 selectively bound to activated G
q·GTP.
|
|
·GTPase activity by PKA and PKG.
ACh stimulated GTPase activity in freshly dispersed smooth muscle cells in a time-dependent fashion. Pretreatment of the cells with isoproterenol or SNP significantly augmented ACh-stimulated GTPase activity (Fig. 5). The pattern reflected phosphorylation of RGS4 and its translocation to the membrane, resulting in increased association of RGS4 and G
q·GTP and acceleration of G
q·GTPase activity. The enhanced inactivation of G
q resulted in decreased activation of PLC-
1.
|
q mutants on ACh-stimulated G
q:RGS4 association and GTPase and PLC-
1 activities.
The role of RGS4 in mediating the inhibitory effect of PKA and PKG on PLC-
1 activity was examined further in cultured smooth muscle cells expressing RGS4(S52A), which lacks the PKA/PKG phosphorylation site. ACh-stimulated PI hydrolysis is control cultured muscle cells (2,596 ± 362 cpm/mg protein above basal levels), and muscle cells expressing RGS4(S52A) (2,935 ± 321 cpm/mg protein) was not significantly different from PI hydrolysis in freshly dispersed smooth muscle cells (2,601 ± 402 cpm/mg protein). Expression of RGS4(S52A) blocked the increase in ACh-stimulated GTPase activity and the decrease in PI hydrolysis induced by PKA and PKG (Fig. 6, A and B). Blockade of PKG-dependent effects was complete, whereas blockade of PKA-dependent effects was only partial. The results implied that inhibition of PI hydrolysis by SNP was solely due to PKG-mediated phosphorylation of RGS4 and subsequent inactivation of G
q, whereas inhibition of PI hydrolysis by isoproterenol was only partly due to PKA-mediated phosphorylation of RGS4 and subsequent inactivation of G
q.
|
q·GTP association induced by PKA or PKG was blocked in cells expressing RGS4(S52A), implying that the increase in association was dependent on RGS4 phosphorylation (Fig. 7). Expression of G
q(G188S), which does not bind RGS4 (57), prevented G
q:RGS4 association (data not shown) and augmented ACh-stimulated PI hydrolysis by
50% (Fig. 8). In these cells, PKG did not inhibit PI hydrolysis, whereas PKA caused only partial inhibition (Fig. 8). The partial inhibition reflected the operation of an additional RGS4-independent mechanism (see below).
|
|

and an NH2-terminal RGS domain that binds G
q and can potentially inhibit PLC-
activity (3, 31, 34). Our group recently showed that phosphorylation of GRK2 by PKA augments GRK2-mediated desensitization of VIP (VPAC2) receptors (39). We postulated that selective phosphorylation of GRK2 by PKA stimulated the ability of the RGS domain in GRK2 to bind G
q and enhance G
q·GTPase activity.
Isoproterenol, but not SNP, induced GRK2 phosphorylation and increased GRK2:G
q·GTP association in the presence of ACh to the same extent in freshly dispersed and cultured smooth muscle cells. Both GRK2 phosphorylation and GRK2:G
q·GTP association were blocked in cultured muscle cells overexpressing GRK2(S685A) (Fig. 9). The mutated Ser685 site is one of three potential (RXS685) sites for phosphorylation by PKA in the COOH terminus of GRK2. Treatment of the cells with isoproterenol or ACh alone did not increase GRK2:G
q·GTP association, implying that GRK2 was selectively bound to activated G
q·GTP and the association was dependent on GRK2 phosphorylation by PKA (Fig. 9).
|
·GTPase activity induced by isoproterenol was only partly inhibited in cells expressing GRK(S685A) (Fig. 10). The residual stimulation reflected the contribution of RGS4. The increase in ACh-stimulated G
·GTPase activity induced by SNP was not affected in cells expressing GRK(S685A) (Fig. 10).
|
q(G188S) and GRK2(S685A), where PKA had no effect on ACh-stimulated PI hydrolysis (Fig. 12). Expression of RGS4, GRK2, and G
q mutants, singly and in combination, demonstrated that PKA inhibited PI hydrolysis by phosphorylating both RGS4 and GRK2 and enhancing their ability to accelerate inactivation of G
q·GTP.
|
|
| DISCUSSION |
|---|
|
|
|---|
isozyme.
In smooth muscle of the gut, Gq-coupled receptor agonists preferentially activate PLC-
1 to stimulate PI hydrolysis and IP3 generation (18, 28). As shown previously (37, 38) and as confirmed in the present study, PLC-
1, unlike PLC-
3, is not a substrate for inhibitory phosphorylation by PKA or PKG. Involvement of a RGS protein is suggested by studies in which PKG inhibited PI hydrolysis in aortic smooth muscle cells expressing wild-type but not dominant negative RGS2 (9, 36). PKG phosphorylated RGS2 and inhibited PLC-
1 activity in aortic muscle cells from control but not RGS/ mice (9, 36). In the present study we have shown that PKA phosphorylates RGS4 and GRK2, which together regulate G
q activity in smooth muscle cells of the gut, whereas PKG selectively phosphorylates RGS4. The stimulatory phosphorylation of RGS4 and GRK2 accelerates deactivation of G
q, resulting in inhibition of PLC-
1 activity.
RGS proteins bind to switch regions in the activated G
subunit and increase its intrinsic GTPase activity (8). The ability of RGS4 and GRK2 to bind G
q·GTP and enhance GTPase activity was augmented upon phosphorylation of both RGS4 and GRK2 by PKA or of RGS4 only by PKG. The rapid inactivation of G
q·GTP precluded further activation of PLC-
1. Several lines of evidence support this notion. First, PKG and PKA induced phosphorylation of RGS4, causing its translocation to the plasma membrane and increasing its association with activated G
q, enhanced ACh-stimulated GTPase activity, and inhibited ACh-stimulated PI hydrolysis. All these effects were dependent on phosphorylation of RGS4 in the case of PKG but only partially dependent on RGS4 in the case of PKA. Expression of phosphorylation-deficient RGS4(S52A) abolished RGS4:G
q association and blocked completely (for PKG) or partly (for PKA) the increase in GTPase activity and the inhibition of PI hydrolysis. Unlike PKG, PKA induced phosphorylation of GRK2, leading to an increase in GRK2:G
q association that contributed to the increase in GTPase activity and the decrease in PI hydrolysis; coexpression of phosphorylation-deficient RGS4(S52A) and GRK2(S685A) completely blocked the inhibition of PI hydrolysis induced by PKA.
Expression of a G
q(G188S), which binds GRK2 but not RGS4 (5, 6), shed further light on the roles of RGS4 and GRK2 in mediating inhibition of PI hydrolysis by PKA and PKG. In the absence of RGS4 binding, ACh-stimulated PI hydrolysis was not inhibited by PKG, and was only partly inhibited by PKA; the partial inhibition by PKA reflected the effect of GRK2, since coexpression of G
q(G188S) and GRK2(S685A) completely blocked the inhibition induced by PKA. The pattern provided further evidence for the participation of RGS4 and GRK2 in inhibition of PI hydrolysis by PKA. Although earlier studies in cell lines had shown that GRK2 bound to activated forms of G
q, G
11, and G
14 and inhibited G
-mediated PI hydrolysis (4), the present study is the first to demonstrate that phosphorylation of GRK2 by PKA augments GRK2 binding to G
q·GTP and enhances the intrinsic GTPase activity of G
q, resulting in inhibition of PI hydrolysis; furthermore, the effect was specific to PKA.
It is worth noting that ACh stimulated PI hydrolysis and GTPase activity and induced association of G
q with RGS4 or GRK2 to the same extent in freshly dispersed and cultured gastric smooth muscle cells in first passage. Furthermore, isoproterenol and SNP inhibited PI hydrolysis, increased ACh-stimulated GTPase activity and association of G
q with GRK2 and/or RGS4 to the same extent in both cell preparations. These similarities provide further confirmation of the functional state of cultured smooth muscle cells.
Relaxation of smooth muscle was mediated by PKA and PKG, and they act on several targets to mediate inhibition of initial and sustained contraction, resulting in MLC20 dephosphorylation and relaxation (18). Relaxation of initial contraction correlated with the decrease in cytosolic Ca2+, which could be achieved by inhibiting IP3 generation and/or by decreasing Ca2+ release from or stimulating Ca2+ uptake into the sarcoplasmic stores. Our previous studies (24, 26, 27) have shown that both PKA and PKG inhibit agonist-stimulated Ca2+ release and that only PKG phosphorylates IP3 receptors and inhibits Ca2+ release. The present studies identify a mechanism for inhibition of IP3 generation by both PKA and PKG via phosphorylation of RGS4 and GRK2 and rapid inactivation of G
q. The importance of this mechanism is in its location at the inception of the signaling cascade that leads to Ca2+ release and MLC20 phosphorylation during initial contraction. Inhibition of IP3 formation and Ca2+ release by PKA and PKG is relevant only to the initial contraction mediated by Ca2+/calmodulin-dependent activation of MLC kinase and MLC20 phosphorylation (18, 28). Sustained contraction is largely Ca2+ independent and reflects inhibition of MLC phosphatase via RhoA-dependent pathways involving phosphorylation of regulatory proteins MYPT1 and CPI-17 that mediate inhibition of MLC phosphatase (28). Relaxation of sustained contraction is mediated by both PKA and PKG via phosphorylation of RhoA at serine 188 and inhibition of RhoA activity (29).
In summary, we have identified a mechanism by which PKA and PKG inhibit agonist-induced PI hydrolysis in smooth muscle cells. Both PKA and PKG phosphorylate RGS4, stimulating its binding to G
q·GTP and enhancing its ability to accelerate the intrinsic GTPase activity of G
q. PKA, but not PKG, also phosphorylates GRK2, leading to a similar enhancement in GTPase activity. The rapid inactivation of G
q·GTP prevents further activation of PLC-
1 and should lead to inhibition of IP3 generation, IP3-dependent Ca2+ release, and initial muscle contraction (Fig. 13). This appears to be the sole mechanism for relaxation mediated by PKA. Relaxation mediated by PKG involves inhibition of PI hydrolysis and IP3-dependent Ca2+ release, as well as inhibitory phosphorylation of IP3 receptors.
|
| GRANTS |
|---|
|
|
|---|
| FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
| REFERENCES |
|---|
|
|
|---|
2. Ali H, Sozzani S, Fisher I, Barr AJ, Richardson RM, Haribabu B, Snyderman R. Differential regulation of formyl peptide and platelet-activating factor receptors. Role of phospholipase
phosphorylation by protein kinase A. J Biol Chem 273: 1101211016, 1998.
3. Carman CV, Parent JL, Day PW, Pronin AN, Sternweis PM, Wedegaertner PB, Gilman AG, Benovic JL, Kozasa T. Selective regulation of G
q/11 by an RGS domain in the G protein-coupled receptor kinase, GRK2. J Biol Chem 274: 3448334492, 1999.
4. Day PW, Carman CV, Sterne-Marr R, Benovic JL, Wedegaertner PB. Differential interaction of GRK2 with members of the G
q family. Biochemistry 42: 91769184, 2003.[CrossRef][Medline]
5. Day PW, Tesmer JJ, Sterne-Marr R, Freeman LC, Benovic JL, Wedegaertner PB. Characterization of the GRK2 binding site of G
q. J Biol Chem 279: 5364353652, 2004.
6. DiBello PR, Garrison TR, Apanovitch DM, Hoffman G, Shuey DJ, Mason K, Cockett MI, Dohlman HG. Selective uncoupling of RGS action by a single point mutation in the G protein
-subunit. J Biol Chem 273: 57805784, 1998.
7. Harris IS, Treskov I, Rowley MW, Heximer S, Kaltenbronn K, Finck BN, Gross RW, Kelly DP, Blumer KJ, Muslin AJ. G-protein signaling participates in the development of diabetic cardiomyopathy. Diabetes 53: 30823090, 2004.
8. Hepler JR. Emerging roles for RGS proteins in cell signalling. Trends Pharmacol Sci 20: 376382, 1999.[CrossRef][Medline]
9. Heximer SP, Knutsen RH, Sun X, Kaltenbronn KM, Rhee MH, Peng N, Oliveira-dos-Santos A, Penninger JM, Muslin AJ, Steinberg TH, Wyss JM, Mecham RP, Blumer KJ. Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice. J Clin Invest 111: 445452, 2003.[CrossRef][Web of Science][Medline]
10. Huang J, Zhou H, Mahavadi S, Sriwai W, Lyall V, Murthy KS. Signaling pathways mediating gastrointestinal smooth muscle contraction and MLC20 phosphorylation by motilin receptors. Am J Physiol Gastrointest Liver Physiol 288: G23G31, 2005.
11. Kamm KE, Stull JT. Dedicated myosin light chain kinases with diverse cellular functions. J Biol Chem 276: 45274530, 2001.
12. Komalavilas P, Lincoln TM. Phosphorylation of the inositol 1,4,5-trisphosphate receptor. Cyclic GMP-dependent protein kinase mediates cAMP and cGMP dependent phosphorylation in the intact rat aorta. J Biol Chem 271: 2193321938, 1996.
13. Kuemmerle JF, Makhlouf GM. Agonist-stimulated cyclic ADP ribose. Endogenous modulator of Ca2+-induced Ca2+ release in intestinal longitudinal muscle. J Biol Chem 270: 2548825494, 1995.
14. Kuemmerle JF, Murthy KS, Makhlouf GM. Longitudinal smooth muscle of the mammalian intestine. A model for Ca2+ signaling by cADPR. Cell Biochem Biophys 28: 3144, 1998.[Medline]
15. Lincoln TM, Cornwell TL. Towards an understanding of the mechanism of action of cyclic AMP and cyclic GMP in smooth muscle relaxation. Blood Vessels 28: 129137, 1991.[Web of Science][Medline]
16. Lincoln TM, Cornwell TL, Rashatwar SS, Johnson RM. Mechanism of cyclic-GMP-dependent relaxation in vascular smooth muscle. Biochem Soc Trans 16: 497499, 1988.[Web of Science][Medline]
17. Liu M, Simon MI. Regulation by cAMP-dependent protein kinase of a G-protein-mediated phospholipase C. Nature 382: 8387, 1996.[CrossRef][Medline]
18. Murthy KS. Signaling for contraction and relaxation in smooth muscle of the gut. Annu Rev Physiol 68: 345374, 2006.[CrossRef][Web of Science][Medline]
19. Murthy KS, Kuemmerle JF, Makhlouf GM. Agonist-mediated activation of PLA2 initiates Ca2+ mobilization in intestinal longitudinal smooth muscle. Am J Physiol Gastrointest Liver Physiol 269: G93G102, 1995.
20. Murthy KS, Makhlouf GM. Adenosine A1 receptor-mediated activation of phospholipase C-
3 in intestinal muscle: dual requirement for
and 
subunits of Gi3. Mol Pharmacol 47: 11721179, 1995.[Abstract]
21. Murthy KS, Makhlouf GM. Differential regulation of phospholipase A2 (PLA2)-dependent Ca2+ signaling in smooth muscle by cAMP- and cGMP-dependent protein kinases. Inhibitory phosphorylation of PLA2 by cyclic nucleotide-dependent protein kinases. J Biol Chem 273: 3451934526, 1998.
22. Murthy KS, Makhlouf GM. Functional characterization of phosphoinositide-specific phospholipase C-
1 and -
3 in intestinal smooth muscle. Am J Physiol Cell Physiol 269: C969C978, 1995.
23. Murthy KS, Makhlouf GM. Heterologous desensitization mediated by G protein-specific binding to caveolin. J Biol Chem 275: 3021130219, 2000.
24. Murthy KS, Makhlouf GM. Interaction of cA-kinase and cG-kinase in mediating relaxation of dispersed smooth muscle cells. Am J Physiol Cell Physiol 268: C171C180, 1995.
25. Murthy KS, Makhlouf GM. Opioid µ,
, and
receptor-induced activation of phospholipase C-
3 and inhibition of adenylyl cyclase is mediated by Gi2 and Go in smooth muscle. Mol Pharmacol 50: 870877, 1996.[Abstract]
26. Murthy KS, Severi C, Grider JR, Makhlouf GM. Inhibition of IP3 and IP3-dependent Ca2+ mobilization by cyclic nucleotides in isolated gastric muscle cells. Am J Physiol Gastrointest Liver Physiol 264: G967G974, 1993.
27. Murthy KS, Zhou H. Selective phosphorylation of the IP3R-I in vivo by cGMP-dependent protein kinase in smooth muscle. Am J Physiol Gastrointest Liver Physiol 284: G221G230, 2003.
28. Murthy KS, Zhou H, Grider JR, Brautigan DL, Eto M, Makhlouf GM. Differential signalling by muscarinic receptors in smooth muscle: m2-mediated inactivation of myosin light chain kinase via Gi3, Cdc42/Rac1 and p21-activated kinase 1 pathway, and m3-mediated MLC20 (20 kDa regulatory light chain of myosin II) phosphorylation via Rho-associated kinase/myosin phosphatase targeting subunit 1 and protein kinase C/CPI-17 pathway. Biochem J 374: 145155, 2003.[CrossRef][Web of Science][Medline]
29. Murthy KS, Zhou H, Grider JR, Makhlouf GM. Inhibition of sustained smooth muscle contraction by PKA and PKG preferentially mediated by phosphorylation of RhoA. Am J Physiol Gastrointest Liver Physiol 284: G1006G1016, 2003.
30. Pedram A, Razandi M, Kehrl J, Levin ER. Natriuretic peptides inhibit G protein activation. Mediation through cross-talk between cyclic GMP-dependent protein kinase and regulators of G protein-signaling proteins. J Biol Chem 275: 73657372, 2000.
31. Sallese M, Mariggio S, D'Urbano E, Iacovelli L, De Blasi A. Selective regulation of Gq signaling by G protein-coupled receptor kinase 2: direct interaction of kinase N terminus with activated G
q. Mol Pharmacol 57: 826831, 2000.
32. Somlyo AP, Somlyo AV. Signal transduction and regulation in smooth muscle. Nature 372: 231236, 1994.[CrossRef][Medline]
33. Somlyo AP, Somlyo AV. Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol 522: 177185, 2000.
34. Sterne-Marr R, Tesmer JJ, Day PW, Stracquatanio RP, Cilente JA, O'Connor KE, Pronin AN, Benovic JL, Wedegaertner PB. G protein-coupled receptor kinase 2/G
q/11 interaction. A novel surface on a regulator of G protein signaling homology domain for binding G
subunits. J Biol Chem 278: 60506058, 2003.
35. Szewczak SM, Behar J, Billett G, Hillemeier C, Rhim BY, Biancani P. VIP-induced alterations in cAMP and inositol phosphates in the lower esophageal sphincter. Am J Physiol Gastrointest Liver Physiol 259: G239G244, 1990.
36. Tang KM, Wang GR, Lu P, Karas RH, Aronovitz M, Heximer SP, Kaltenbronn KM, Blumer KJ, Siderovski DP, Zhu Y, Mendelsohn ME. Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure. Nat Med 9: 15061512, 2003.[CrossRef][Web of Science][Medline]
37. Xia C, Bao Z, Yue C, Sanborn BM, Liu M. Phosphorylation and regulation of G-protein-activated phospholipase C-
3 by cGMP-dependent protein kinases. J Biol Chem 276: 1977019777, 2001.
38. Yue C, Dodge KL, Weber G, Sanborn BM. Phosphorylation of serine 1105 by protein kinase A inhibits phospholipase C
3 stimulation by G
q. J Biol Chem 273: 1802318027, 1998.
39. Zhou H, Grider JR, Murthy KS. Agonist-dependent, PKA-mediated phosphorylation of GRK2 augments homologous desensitization of VPAC2 receptors in smooth muscle (Abstract). Gastroenterology 122: A256, 2002.[CrossRef]
This article has been cited by other articles:
![]() |
M. Zhong, D. A. Murtazina, J. Phillips, C.-Y. Ku, and B. M. Sanborn Multiple Signals Regulate Phospholipase CBeta3 in Human Myometrial Cells Biol Reprod, June 1, 2008; 78(6): 1007 - 1017. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Bender, P. Nasrollahzadeh, M. Timpert, B. Liu, L. Pott, and M.-C. Kienitz A role for RGS10 in {beta}-adrenergic modulation of G-protein-activated K+ (GIRK) channel current in rat atrial myocytes J. Physiol., April 15, 2008; 586(8): 2049 - 2060. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. S. Murthy, S. Mahavadi, J. Huang, H. Zhou, and W. Sriwai Phosphorylation of GRK2 by PKA augments GRK2-mediated phosphorylation, internalization, and desensitization of VPAC2 receptors in smooth muscle Am J Physiol Cell Physiol, February 1, 2008; 294(2): C477 - C487. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |